MX2007007472A - Derivados de triazolona, tetrazolona e imidazolona para uso como antagonista del adrenorreceptor alfa-2c. - Google Patents
Derivados de triazolona, tetrazolona e imidazolona para uso como antagonista del adrenorreceptor alfa-2c.Info
- Publication number
- MX2007007472A MX2007007472A MX2007007472A MX2007007472A MX2007007472A MX 2007007472 A MX2007007472 A MX 2007007472A MX 2007007472 A MX2007007472 A MX 2007007472A MX 2007007472 A MX2007007472 A MX 2007007472A MX 2007007472 A MX2007007472 A MX 2007007472A
- Authority
- MX
- Mexico
- Prior art keywords
- disorders
- tetrazolone
- triazolone
- imidazolone derivatives
- alpha
- Prior art date
Links
- WZELXJBMMZFDDU-UHFFFAOYSA-N Imidazol-2-one Chemical class O=C1N=CC=N1 WZELXJBMMZFDDU-UHFFFAOYSA-N 0.000 title abstract 2
- OUOJIFQQBPKAMU-UHFFFAOYSA-N tetrazol-5-one Chemical compound O=C1N=NN=N1 OUOJIFQQBPKAMU-UHFFFAOYSA-N 0.000 title abstract 2
- FFSJPOPLSWBGQY-UHFFFAOYSA-N triazol-4-one Chemical compound O=C1C=NN=N1 FFSJPOPLSWBGQY-UHFFFAOYSA-N 0.000 title abstract 2
- 229940082496 Adrenoreceptor antagonist Drugs 0.000 title 1
- 102100025983 Alpha-2C adrenergic receptor Human genes 0.000 title 1
- 101710149275 Alpha-2C adrenergic receptor Proteins 0.000 title 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 2
- 208000019022 Mood disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 206010012335 Dependence Diseases 0.000 abstract 1
- 125000000815 N-oxide group Chemical group 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000000674 adrenergic antagonist Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 208000022821 personality disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04106817 | 2004-12-21 | ||
| EP05104873 | 2005-06-03 | ||
| PCT/EP2005/056951 WO2006067139A1 (en) | 2004-12-21 | 2005-12-20 | Triazolone, tetrazolone and imidazolone derivatives for use as alpha-2c adrenoreceptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007007472A true MX2007007472A (es) | 2007-07-20 |
Family
ID=36013649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007007472A MX2007007472A (es) | 2004-12-21 | 2005-12-20 | Derivados de triazolona, tetrazolona e imidazolona para uso como antagonista del adrenorreceptor alfa-2c. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20100029620A1 (enExample) |
| EP (1) | EP1831185A1 (enExample) |
| JP (1) | JP2008524312A (enExample) |
| KR (1) | KR20070090941A (enExample) |
| AR (1) | AR052342A1 (enExample) |
| AU (1) | AU2005318188A1 (enExample) |
| BR (1) | BRPI0516380A (enExample) |
| CA (1) | CA2588028A1 (enExample) |
| EA (1) | EA011514B1 (enExample) |
| IL (1) | IL184048A0 (enExample) |
| MX (1) | MX2007007472A (enExample) |
| NO (1) | NO20073760L (enExample) |
| PA (1) | PA8657301A1 (enExample) |
| TW (1) | TW200635906A (enExample) |
| WO (1) | WO2006067139A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2627221T3 (es) | 2006-12-28 | 2017-07-27 | Rigel Pharmaceuticals, Inc. | Compuestos de heterocicloalquiloxibenzamida N-sustituidos y métodos de uso |
| CA2798330A1 (en) | 2010-05-05 | 2011-11-10 | Infinity Pharmaceuticals, Inc. | Tetrazolones as inhibitors of fatty acid synthase |
| HRP20150462T1 (hr) * | 2010-10-01 | 2015-07-17 | Taisho Pharmaceutical Co., Ltd | Derivat 1,2,4-triazolona |
| FR2976287B1 (fr) | 2011-06-09 | 2013-07-05 | Pf Medicament | Derives benzoquinolizidines, leur procede de preparation et leurs applications en therapeutique |
| SI2772482T1 (sl) * | 2011-10-27 | 2016-06-30 | Taisho Pharmaceutical Co., Ltd. | Derivat azola |
| CN104334547B (zh) | 2012-05-22 | 2017-06-06 | 奥蒂福尼疗法有限公司 | 作为kv3抑制剂的三唑类 |
| CN105283452B (zh) * | 2013-06-11 | 2019-01-04 | 豪夫迈·罗氏有限公司 | 四唑酮衍生物 |
| US10111879B2 (en) | 2013-06-27 | 2018-10-30 | Cedars-Sinai Medical Center | Adrenoceptors antagonists for the prevention and treatment of neurodegenerative conditions |
| AU2017295745A1 (en) | 2016-07-12 | 2019-01-31 | Bayer Cropscience Aktiengesellschaft | Bicyclic compounds as pest control agents |
| CA3079819C (en) * | 2017-11-06 | 2023-03-14 | Acelot, Inc. | Small molecule drugs and related methods for treatment of diseases related to a.beta.42 oligomer formation |
| JP2021183586A (ja) * | 2020-05-22 | 2021-12-02 | 武田薬品工業株式会社 | 複素環化合物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3355457A (en) * | 1965-05-21 | 1967-11-28 | American Cyanamid Co | Substituted 2-imidazolinones |
| DE2725148A1 (de) * | 1977-06-03 | 1978-12-14 | Hoechst Ag | 1-aryl-4-alkyl-1,2,4-triazol-5-one und verfahren zu ihrer herstellung |
| SG48386A1 (en) * | 1994-01-24 | 1998-04-17 | Janssen Pharmaceutica Nv | Watersoluble azole antifungals |
| JPH0899975A (ja) * | 1994-08-05 | 1996-04-16 | Nippon Bayeragrochem Kk | ５員複素環置換テトラゾリノン誘導体および除草剤 |
| JPH09183770A (ja) * | 1995-10-31 | 1997-07-15 | Nippon Bayeragrochem Kk | １−アジン−テトラゾリノン類及び除草剤 |
| WO1998025912A1 (en) * | 1996-12-13 | 1998-06-18 | E.I. Du Pont De Nemours And Company | Herbicidal heterocyclic amides |
| WO1998051683A1 (en) * | 1997-05-15 | 1998-11-19 | E.I. Du Pont De Nemours And Company | Herbicidal tetrazolinones |
| EP0957101A1 (en) * | 1998-05-14 | 1999-11-17 | Janssen Pharmaceutica N.V. | Water soluble azoles as broad-spectrum antifungals |
| AU5301799A (en) * | 1998-08-19 | 2000-03-14 | Hokko Chemical Industry Co. Ltd. | Triazolinone derivatives and herbicide compositions |
| JP3837242B2 (ja) * | 1998-08-25 | 2006-10-25 | 北興化学工業株式会社 | トリアゾリノン誘導体および除草剤 |
-
2005
- 2005-12-19 AR ARP050105336A patent/AR052342A1/es not_active Application Discontinuation
- 2005-12-20 MX MX2007007472A patent/MX2007007472A/es unknown
- 2005-12-20 EA EA200701345A patent/EA011514B1/ru not_active IP Right Cessation
- 2005-12-20 WO PCT/EP2005/056951 patent/WO2006067139A1/en not_active Ceased
- 2005-12-20 AU AU2005318188A patent/AU2005318188A1/en not_active Abandoned
- 2005-12-20 US US11/722,380 patent/US20100029620A1/en not_active Abandoned
- 2005-12-20 KR KR1020077014061A patent/KR20070090941A/ko not_active Withdrawn
- 2005-12-20 JP JP2007547485A patent/JP2008524312A/ja active Pending
- 2005-12-20 BR BRPI0516380-3A patent/BRPI0516380A/pt not_active IP Right Cessation
- 2005-12-20 PA PA20058657301A patent/PA8657301A1/es unknown
- 2005-12-20 CA CA002588028A patent/CA2588028A1/en not_active Abandoned
- 2005-12-20 EP EP05823472A patent/EP1831185A1/en not_active Withdrawn
- 2005-12-21 TW TW094145703A patent/TW200635906A/zh unknown
-
2007
- 2007-06-19 IL IL184048A patent/IL184048A0/en unknown
- 2007-07-19 NO NO20073760A patent/NO20073760L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1831185A1 (en) | 2007-09-12 |
| JP2008524312A (ja) | 2008-07-10 |
| EA011514B1 (ru) | 2009-04-28 |
| BRPI0516380A (pt) | 2008-09-02 |
| AR052342A1 (es) | 2007-03-14 |
| AU2005318188A1 (en) | 2006-06-29 |
| WO2006067139A1 (en) | 2006-06-29 |
| CA2588028A1 (en) | 2006-06-29 |
| NO20073760L (no) | 2007-07-19 |
| EA200701345A1 (ru) | 2007-10-26 |
| US20100029620A1 (en) | 2010-02-04 |
| PA8657301A1 (es) | 2007-01-17 |
| TW200635906A (en) | 2006-10-16 |
| IL184048A0 (en) | 2007-10-31 |
| KR20070090941A (ko) | 2007-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007135131A8 (en) | Substituted pyrazinone derivatives for use as a medicine | |
| IL198072A0 (en) | Substituted pyrazinone derivatives for use as a medicine | |
| NO20073760L (no) | Triazolon-, tetrazolon- og imidazolonderivater for anvendelse som alfa-2C-adrenoreseptorantagonister | |
| TW200420550A (en) | Thiazole compounds for the treatment of neurodegenerative disorders | |
| DK1303495T3 (da) | Substituerede 5-alkylnylpyrimidiner med neurotrofisk aktivitet | |
| TW200531689A (en) | Therapeutic agents | |
| WO2007141200A8 (en) | Novel n-aryl and n-heteroaryl substituted pyridinone derivatives for use in mch-1 mediated diseases | |
| WO2007002516A3 (en) | Improved dosage forms for movement disorder treatment | |
| WO2007038209A3 (en) | Fused tetracyclic mglur1 antagonists as therapeutic agents | |
| TW200504034A (en) | Therapeutic agents | |
| TW200635903A (en) | Therapeutic agents | |
| MY141736A (en) | Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists | |
| TW200745135A (en) | Therapeutic agents | |
| CA2498291A1 (en) | Diazabicyclic compounds useful in the treatment of cns and other disorders | |
| TW200633986A (en) | Therapeutic agents | |
| WO2007070393A3 (en) | Mglur1 anatgonists as therapeutic agents | |
| TW200509933A (en) | Therapeutic agents | |
| MY142431A (en) | Oxadiazolones, processes for their preparation and their use as pharmaceuticals | |
| TW200635589A (en) | Therapeutic agents | |
| IL192240A0 (en) | Substituted pyrazinone derivatives as alpha2c-adrenoreceptor antagonists | |
| IL194740A0 (en) | Substituted pyrazinone derivatives for use as a medicine | |
| MX2007006754A (es) | Derivados de indenilo y uso de los mismos para el tratamiento de trastornos neurologicos. | |
| MY136718A (en) | Sulfonamide compounds for the treatment of neurodegenerative disorders | |
| WO2005095348A3 (en) | Pyrazole-amine compounds for the treatment of neurodegenerative disorders | |
| MX2010009820A (es) | 2-aminoquinolinas como antagonistas del receptor 5-hidroxitriptamina 5a. |